dc.contributor.author |
Jung, Susanne |
|
dc.contributor.author |
Nelde, Annika |
|
dc.contributor.author |
Maringer, Yacine |
|
dc.contributor.author |
Denk, Monika |
|
dc.contributor.author |
Zieschang, Lisa |
|
dc.contributor.author |
Kammer, Christine |
|
dc.contributor.author |
Martus, Peter |
|
dc.contributor.author |
Hackenbruch, Christopher |
|
dc.contributor.author |
Englisch, Alexander |
|
dc.contributor.author |
Heitmann, Jonas S. |
|
dc.contributor.author |
Salih, Helmut R. |
|
dc.contributor.author |
Walz, Juliane S. |
|
dc.contributor.author |
Oezbek, Melek T. |
|
dc.date.accessioned |
2025-05-13T05:49:07Z |
|
dc.date.available |
2025-05-13T05:49:07Z |
|
dc.date.issued |
2024 |
|
dc.identifier.issn |
2234-943X |
|
dc.identifier.uri |
http://hdl.handle.net/10900/165478 |
|
dc.language.iso |
en |
de_DE |
dc.publisher |
Lausanne : Frontiers Media Sa |
de_DE |
dc.relation.uri |
http://dx.doi.org/10.3389/fonc.2024.1458449 |
de_DE |
dc.subject.ddc |
610 |
de_DE |
dc.title |
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients |
de_DE |
dc.type |
Article |
de_DE |
utue.quellen.id |
20250203000000_00898 |
|
utue.personen.roh |
Jung, Susanne |
|
utue.personen.roh |
Nelde, Annika |
|
utue.personen.roh |
Maringer, Yacine |
|
utue.personen.roh |
Denk, Monika |
|
utue.personen.roh |
Zieschang, Lisa |
|
utue.personen.roh |
Kammer, Christine |
|
utue.personen.roh |
Oezbek, Melek |
|
utue.personen.roh |
Martus, Peter |
|
utue.personen.roh |
Hackenbruch, Christopher |
|
utue.personen.roh |
Englisch, Alexander |
|
utue.personen.roh |
Heitmann, Jonas S. |
|
utue.personen.roh |
Salih, Helmut R. |
|
utue.personen.roh |
Walz, Juliane S. |
|
dcterms.isPartOf.ZSTitelID |
Frontiers in Oncology |
de_DE |
dcterms.isPartOf.ZS-Issue |
Article 1458449 |
de_DE |
dcterms.isPartOf.ZS-Volume |
14 |
de_DE |
utue.fakultaet |
04 Medizinische Fakultät |
de_DE |